Table 2

Biochemical parameters at baseline (week 0) and end of treatment (week 12) with FTP or placebo in subjects with elevated ALT levels
FTP group (n = 26) Placebo group (n = 22) P-value1)
Baseline 12 week Baseline 12 week
ALT (IU/L)
Mean ± SD 61.1 ± 25.1 44.9 ± 15.5 55.7 ± 15.1 53.8 ± 26.3 0.019*
Median(Range) 51.5(41–151) 42.5(19–95) 49(40–85) 51(22–127) -
AST (IU/L)
Mean ± SD 36.3 ± 13.8 27.9 ± 7.9 35.6 ± 8.8 34.8 ± 10.9 0.020*
Median(Range) 32.5(20–73) 27(17–46) 34(25–57) 33.5(21–55) -
ALP (IU/L)
Mean ± SD 85.0 ± 19.3 80.0 ± 21.9 71.7 ± 13.5 68.9 ± 13.2 0.471
Median(Range) 81.5(52–144) 79(46–160) 69(48–101) 69(43–92) -
gamma-GT (IU/L)
Mean ± SD 86.3 ± 71.5 66.9 ± 45.6 104.3 ± 69.0 100.8 ± 68.4 0.254
Median(Range) 64(26–360) 52(23–195) 95(16–231) 91(17–253) -
Total bilirubin (mg/dL)
Mean ± SD 0.98 ± 0.46 0.88 ± 0.38 0.89 ± 0.28 0.84 ± 0.26 0.664
Median(Range) 0.87(0.37-2.29) 0.79(0.4-1.98) 0.9(0.37-1.37) 0.81(0.37-1.34) -

Values are presented as mean ± SD.

1. Linear mixed model for repeated measures data.

*P <0.05.

Kim et al.

Kim et al. BMC Complementary and Alternative Medicine 2013 13:58   doi:10.1186/1472-6882-13-58

Open Data